^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Excerpt:
Confirmed BOR as per RECIST 1.1 as adjudicated by an Independent Endpoint Review Committee (IERC) for secondary urothelial carcinoma cohort [ Time Frame: Time Frame: Every 6 weeks for first 12 months, then 12-weekly until end of treatment and post treatment every 3 months ( up to 52 months) ]
Trial ID:
Source:
Title:
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Excerpt:
Among evaluable patients in the 1 L subgroup with PD-L1+ (n = 20) or PD-L1− (n = 21) tumors, respectively, the ORR was 10.0% (95% CI, 2.7–24.5) and 14.3% (95% CI, 5.4–29.1), median PFS was 5.8 months (95% CI, 1.9–13.0) and 8.3 months (95% CI, 5.5–15.1), 6-month PFS rates were 48.5% (95% CI, 25.4–68.2) and 66.7% (95% CI, 42.5–82.5), median OS was not evaluable in either group, and 12-month OS rates were 85.0% (95% CI, 60.4–94.9) and 90.5% (95% CI, 67.0–97.5).
DOI:
https://doi.org/10.1186/s40425-019-0746-2
Trial ID:
